Organogenesis Reports Positive Interim Analysis of Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis
01 mars 2023 16h01 HE
|
Organogenesis Holdings Inc.
CANTON, Mass. , March 01, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization...
Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2022 Financial Results on March 1, 2023
09 févr. 2023 07h30 HE
|
Organogenesis Holdings Inc.
CANTON, Mass., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization...
Organogenesis Holdings Inc. to Participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech Conference
05 déc. 2022 07h30 HE
|
Organogenesis Holdings Inc.
CANTON, Mass., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of...
Organogenesis Holdings Inc. Reports Third Quarter 2022 Financial Results
09 nov. 2022 16h05 HE
|
Organogenesis Holdings Inc.
CANTON, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of...
Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2022 Financial Results on November 9, 2022
26 sept. 2022 09h12 HE
|
Organogenesis Holdings Inc.
CANTON, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization...
Organogenesis Holdings Inc. to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
07 sept. 2022 07h30 HE
|
Organogenesis Holdings Inc.
CANTON, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization...
Organogenesis Receives FDA Clearance for Next Generation PuraPly Surgical Solution
15 août 2022 07h00 HE
|
Organogenesis Holdings Inc.
CANTON, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Organogenesis, a leading regenerative medicine company, today announced it has received U.S. Food and Drug Administration (FDA) 510k Clearance for...
Organogenesis Holdings Inc. Reports Second Quarter 2022 Financial Results
09 août 2022 16h05 HE
|
Organogenesis Holdings Inc.
CANTON, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of...
Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2022 Financial Results on August 9, 2022
30 juin 2022 07h30 HE
|
Organogenesis Holdings Inc.
CANTON, Mass., June 30, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of...
Organogenesis Holdings Inc. Reports First Quarter 2022 Financial Results
10 mai 2022 16h05 HE
|
Organogenesis Holdings Inc.
CANTON, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of...